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Background: Cytomegalovirus (CMV) infection has been reported to contribute to the pathogenesis of type 1
diabetes and post-transplantation diabetes. However, CMV infection has not been evaluated as a possible risk factor
for type 2 diabetes. Our aim was to investigate potential associations between CMV seropositivity, CMV IgG
antibody level and glucose regulation in the oldest old.
Results: CMV seropositive subjects were more likely to have type 2 diabetes (17.2% vs 7.9%, p = 0.016), had a higher
level of HbA1c (p = 0.014) and higher non-fasting glucose (p = 0.024) in the oldest olds. These associations remained
significant after adjustment for possible confounders. CMV IgG antibody level was not significantly associated with
glucose regulation (all p > 0.05).
Conclusions: In the oldest old, CMV seropositivity is significantly associated with various indicators of glucose
regulation. This finding suggests that CMV infection might be a risk factor for the development of type 2 diabetes
in the elderly.
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The increasing prevalence of type 2 diabetes can be
attributed to the growing proportion of elderly and the
higher incidence of type 2 diabetes among younger indi-
viduals in developed countries. Obesity, inactivity and
ageing are associated with insulin resistance. When pan-
creatic islets progressively fail to enhance production of
insulin as compensation for insulin resistance, insulin
deficiency, chronic hyperglycaemia and eventually type 2
diabetes will develop. However, while only one third of
individuals with insulin resistance will ultimately develop
type 2 diabetes, many others do not because their β-cells
are able to respond adequately to the increased demand
for insulin [1,2]. The reason for this heterogeneity is not* Correspondence: A.B.Maier@lumc.nl
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reproduction in any medium, provided the orcompletely understood. In the pathogenesis of type 2
diabetes, several genetic [3], epigenetic [4] and environ-
mental [5] factors are believed to contribute, while
chronic inflammation is also suggested to be a character-
istic feature of the disease. Systemic markers in type 2
diabetes are shifted towards a more pro-inflammatory
status, including elevated C-reactive protein (CRP) and
fibrinogen levels and greater numbers and a more acti-
vated state of various leukocyte populations [2,6]. Des-
pite accumulating evidence that chronic inflammation is
a risk factor for type 2 diabetes [2,6,7], there is only lim-
ited knowledge whether infection by specific pathogens
contributes to inflammation and the subsequent inci-
dence of type 2 diabetes.
A chronic stressor for the immune system is the com-
mon herpes virus cytomegalovirus (CMV) which estab-
lishes persistent, life-long infections and can become
reactivated periodically [8,9]. CMV seropositivity was
clustered as one parameter of the “Immune Risk Profile”td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and syndromes with an inflammatory component in-
cluding cancer [11,12], cardiovascular disease [13], frailty
[14], functional impairment [15] and cognitive impair-
ment [16,17], and mortality [18]. Therefore, active CMV
infection or reactivation from a latent state is considered
potentially a cofactor for inflammatory disease [12]. Sev-
eral findings suggest that persistent CMV infection may
participate in the pathogenesis of type 2 diabetes. CMV
may accelerate immunosenescence by inducing the accu-
mulation of late-differentiated CD4+ and CD8+ T-cells
which produce pro-inflammatory cytokines and thereby
generate a more pro-inflammatory environment [19-21].
Furthermore, pro-inflammatory cytokines were reported
to have deleterious effects on pancreatic β-cells which
could lead to an insufficient response to insulin resist-
ance, resulting in onset of type 2 diabetes [22]. More-
over, non-symptomatic CMV infection is known to be
a risk factor for the development of new-onset post-
transplantation diabetes (PTDM) [23]. In one study, CMV
RNA was identified in the pancreas of patients with type 2
diabetes, localized primarily in the islets of Langerhans
[24], but a different study failed to detect CMV DNA in
the pancreas of such patients [25]. However, recently it
was shown that human pancreatic β-cells are susceptible
to CMV infection [26]. At the population level, a clear
positive association between CMV infection and type 2
diabetes has not yet been reported [27-30].
The aim of the present study was to explore the asso-
ciation between CMV seropositivity, CMV IgG antibody
level, and indicators of glucose regulation assessed by
means of the frequency of diagnosis of type 2 diabetes,
level of glycated haemoglobin (HbA1c) and level of non-
fasting glucose in a cohort of the oldest old in the gen-
eral population.
Results
Table 1 summarizes the baseline characteristics of the
study population stratified by CMV serostatus (n = 549).
All participants were 85 years of age, the majority were
CMV-seropositive (n = 435, 79.2%). CMV-seropositive
participants were more often female, had lower educa-
tion level and lower income (all p < 0.05).
Table 2 shows associations between CMV seropositiv-
ity and indicators of glucose regulation expressed as the
frequency of diagnosis of type 2 diabetes, level of HbA1c
and level of non-fasting glucose (n = 547). The frequency
of type 2 diabetes was 15% (n = 84) of the entire popula-
tion. Diagnosis of type 2 diabetes (p = 0.014), level of
HbA1c (p = 0.016) and non-fasting glucose (p = 0.024)
were all significantly higher in CMV seropositive partici-
pants. These associations remained significant after ad-
justment for possible confounders. The findings are
depicted in Figure 1.Table 3 shows the association between CMV IgG anti-
body level and the diagnosis of type 2 diabetes, level of
HbA1c and non-fasting glucose, in CMV seropositive
participants (n = 432). CMV IgG antibody level was not
associated with any of the markers of glucose regulation
(all p > 0.05).
Discussion
In the present study, CMV seropositivity was associated
with indicators of glucose regulation in terms of more
frequent diagnoses of type 2 diabetes, elevated levels of
HbA1c and non-fasting glucose in very elderly people
infected with this virus. The titer of CMV IgG antibody,
however, was not significantly associated with these indi-
cators. Our findings suggest a role for CMV infection in
the pathogenesis of type 2 diabetes in the elderly.
CMV might be involved in accelerating pancreatic fail-
ure to compensate for insulin resistance via at least two
possible mechanisms. First, it could influence the pan-
creatic cells directly; secondly, it might act indirectly by
influencing the immune system which in turn affects the
pancreas. Consistent with the first possibility is the re-
port that CMV may infect and reside in pancreatic cells
without causing cytopathic effects but nonetheless influ-
encing insulin production directly after repeated reacti-
vations [24]. Additionally, infection of human pancreatic
β-cells with CMV induced the release of pro-
inflammatory cytokines and increased cellular immuno-
genicity [26]. The indirect effects of CMV could be
exerted via infected monocyte production of IL-1β
which induces TNF-α production in human pancreatic
duct cells, driving cells into apoptosis and thus com-
promising β-cell function [24,31]. Other components of
the immune system, influenced by prolonged CMV in-
fection, could hypothetically also contribute to a more
pro-inflammatory environment, which is an important
feature of type 2 diabetes [2]. CMV seropositivity is asso-
ciated with accumulations of potentially senescent late-
differentiated T-cells and elevated numbers of CD4+ and
CD8+ effector cells [32] which are more likely to pro-
duce pro-inflammatory cytokines [21].
Thus far, no relationships between glucose regulation
and CMV seropositivity had been confirmed at the
population level [27-30]. Three earlier studies investi-
gated notably younger participants with comorbidities in
relatively small cohorts [27-29]. Age, ethnicity, income
and education (socioeconomic factors) have not always
been considered important confounders for CMV and
diseases, although this is very likely to be the case espe-
cially for the latter [33,34]. In 1000 participants aged
45–84 years in the Multiethnic study of atherosclerosis
(MESA), associations between CMV infection, pathogen
burden > 3 and diagnoses of type 2 diabetes were indeed
observed. After adjustment for demographic covariates
Table 1 Characteristics of the participants, aged 85 years (n = 549), stratified by CMV serostatus
CMV-serostatus
positive (n = 435) negative (n = 114)
Gender: women, n (%) 303 (69.7) 65 (57.0)
Education: low, n (%) 313 (72.5) 45 (39.5)
Income: low, n (%) 238 (55.5) 41 (36.6)
BMI (kg/m2), mean (SD) 27.4 (4.5) 26.6 (4.6)
Smoking: ever, n (%) 199 (46.1) 62 (54.4)
Alcohol (units/week), median (IQR) 0 (0-3) 1 (0-7)
Comorbidities:
Diabetes, n (%) 75 (17.2) 9 (7.9)
COPD, n (%) 51 (12.0) 12 (10.9)
Parkinson, n (%) 11 (2.6) 1 (0.9)
Cancer, n (%) 68 (16.0) 27 (24.5)
Arthritis, n (%) 140 (33.0) 31 (28.2)
Sumscore of cardiovascular comorbidities, mean (SD) 3.9 (19.7) 3.0 (13.3)
Total number of comorbidities, mean (SD) 4.8 (19.8) 3.8 (13.4)
Total number of medications, mean (SD) 3.3 (2.7) 3.0 (2.6)
CRP (mg/L)*, mean (SD) 0.8 (1.7) 1.0 (1.8)
*CRP (mg/L) is logtransformed.
BMI: body mass index. CRP: C-reactive protein. COPD: chronic obstructive pulmonary disease. Sumscore of cardiovascular comorbidities: hypertension, myocardial
infarction, angina pectoris, claudicatio intermittens, arterial surgery and stroke. Total number of comorbidities: sumscore of cardiovascular comorbidities, COPD,
Parkinson, Cancer, Arthritis.
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became non-significant, suggesting no aetiological role
for pathogens/CMV in the occurrence of type 2 diabetes
[29].
Three possible explanations for why positive relation-
ship of CMV seropositivity with glucose regulation
emerges in the oldest old can be given. First, the direct
deleterious effects of CMV infection on pancreatic cells
might only become significant after a long period of acti-
vation and reactivation of CMV and therefore only de-
tectable in the oldest old. Second, systemic inflammationTable 2 Associations between CMV serostatus and indicators






Non-fasting glucose* (mmol/l) Model
Model
Model
*Non-fasting glucose (mmol/l) is logtransformed.
OR: Odds Ratio, 95% CI: Confidence Interval.
Model 1 (n = 547): Not adjusted (crude model).
Model 2 (n = 510): Adjusted for gender, income, education, smoking, body mass ind
Model 3 (n = 510): Model 2 and adjusted for logtransformed C-reactive protein.may interfere with the action of insulin on cells by sup-
pressing intracellular insulin signal transduction [35].
This possible indirect systemic effect of CMV infection
on the immune system would also take time to develop.
Third, our study population of 85-year-olds is of course
highly selected for longer-than-average survival, and has
thus already lost individuals with other known risk fac-
tors for cardiovascular diseases and type 2 diabetes.
These risk factors could have overshadowed the impact
of CMV infection in glucose regulation in younger
people.of glucose regulation
OR (95% CI) P value
1 2.44 (1.18;5.05) 0.016
2 2.35 (1.04;5.31) 0.041
3 2.42 (1.07;5.49) 0.034
1 1.37 (1.07;1.77) 0.014
2 1.41 (1.05;1.90) 0.024
3 1.44 (1.07;1.95) 0.017
1 2.23 (1.11;4.48) 0.024
2 2.46 (1.05;5.76) 0.039
3 2.50 (1.06;5.88) 0.036
ex, total number of comorbidities and total number of medications.
(a) Prevalence of type 2 diabetes (in percentage of subjects) 
(b) Level of HbA1c (in percentage of glycated haemoglobin)  
(c) Level of non-fasting glucose (in mmol/L).  
HbA1c: level of glycated haemoglobin 
*P<0.05  
Figure 1 Comparison of glucose regulation in relation to CMV serostatus. (a) Prevalence of type 2 diabetes (in percentage of subjects),
(b) Level of HbA1c (in percentage of glycated haemoglobin). (c) Level of non-fasting glucose (in mmol/L). HbA1c: level of glycated haemoglobin
*P < 0.05.
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may impair host defenses, predispose to infection and
therefore leads to a higher seroprevalence of CMV in
diabetic patients [36]. Thus, higher prevalence of CMV
would be a result, not a cause, of disease. However,
CMV infection is often acquired during childhood. Once
the host is infected, the virus persists in various tissues.
The chance of becoming infected with CMV is highly
influenced by socioeconomic conditions and close con-
tacts allowing the virus to spread [33,34]. It is therefore
unlikely that diabetes precedes CMV infection, but itTable 3 Associations between CMV IgG antibody level
and indicators of glucose regulation
Beta (SE) P value
Diagnosis of type 2 diabetes
(0 = no, 1 = yes)
Model 1 1.44 (1.17) 0.220
Model 2 1.70 (1.27) 0.182
Model 3 1.86 (1.27) 0.144
Hba1c(%) Model 1 0.47 (0.39) 0.226
Model 2 0.49 (0.42) 0.240
Model 3 0.56 (0.42) 0.181
Non-fasting glucose* (mmol/l) Model 1 1.19 (1.40) 0.185
Model 2 2.38 (1.52) 0.119
Model 3 2.44 (1.52) 0.110
*Non-fasting glucose (mmol/l) is logtransformed.
SE: Standard error.
Model 1 (n = 432): Not adjusted (crude model).
Model 2 (n = 404): Adjusted for gender, income, education, smoking, body
mass index, total number of comorbidities and total number of medications.
Model 3 (n = 404): Model 2 and adjusted for logtransformed CRP.still cannot be ruled out that there are undetected pre-
disposing factors to both diabetes and CMV infection.
In the present study, CMV IgG antibody titer did not
associate significantly with diagnoses of type 2 diabetes
in the oldest old. Although CMV antibody level has been
reported to associate with mortality among community-
dwelling older adults [37,38], it is still unclear what the
clinical implications of CMV antibody level on the onset
of diseases may be and what the effect of chronological
age on CMV antibody level is [39,40]. Recently, CMV
antibody level has been reported not to be related to any
major genetic determinants either [41].
The cross-sectional nature of the relationship between
CMV seropositivity and indicators of glucose regulation
is one limitation of our study. One cross-sectional study
is not sufficient to prove whether the contribution of
CMV infection is causative. This relationship should be
confirmed in studies with a prospective design in
younger participants with long-term follow-up and regu-
lar monitoring of incidence of CMV infection. A second
limitation is that the blood samples were collected under
non-fasting conditions. It is therefore likely that we have
underestimated the effect of CMV seropositivity on glu-
cose level, which would increase the robustness of our
findings. Still, the old age of the participants could limit
the applicability of these findings to the general popula-
tion, but the fact that our study population is relatively
large and all participants were 85 years of age could also
be seen as a strength. It might be feasible to study the
effect of CMV seropositivity only in such special
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nounced after years of latent infection plus periodic
reactivations. The large size of our study and the homo-
geneity of the age could have made the impact of CMV
easier to determine.
Our finding that CMV seropositivity is associated with
more diagnoses of type 2 diabetes in the oldest olds
leads to the hypothesis that CMV seropositivity may fa-
cilitate the onset of type 2 diabetes in the long term. It is
crucial to demonstrate the association using a prospect-
ive study design, starting with a younger study popula-
tion, as CMV infection may be a “hidden” cause of
morbidity [18].
Conclusions
The present study is the first to show that CMV sero-
positivity is positively independently associated with
indicators of glucose regulation. Our findings shed light
on the pathogenesis of type 2 diabetes in the very eld-
erly. More research needs to be performed to determine




The Leiden 85-plus Study is a prospective population-
based follow-up study of inhabitants of the city of Lei-
den, the Netherlands. The over-all aim of this study was
to investigate determinants of successful ageing. All
inhabitants who reached the age of 85 years were eligible
to participate. There were no selection criteria on health,
functioning or demographic characteristics. Enrolment
took place between 1997 and 1999. In total, 599 indivi-
duals participated in the study, 87% of all eligible indivi-
duals. Details were provided in a previous publication
[42]. All participants gave informed consent. For persons
with severe cognitive impairment, informed consent was
given by a guardian.
CMV serostatus and CMV IgG antibody level
For the current analysis, we included 549 participants
with information on CMV serostatus and antibody level
determined by the CMV IgG kit (ETI-CYTOK-G PLUS
DiaSorin, Saluggia, Italy) based on enzyme immunoassay
technology. Anti-CMV IgG antibody levels were
expressed as antibody units/ml.
Diagnosis of type 2 diabetes, level of HbA1c and
determination of non-fasting glucose
Diagnosis of type 2 diabetes at baseline was defined by:
1) reporting the use of oral anti-diabetes medication or
the use of insulin based on information obtained from
the participant’s pharmacist; 2) treatment by diet, or
registration by a general practitioner as having diabetes;or 3) non-fasting glucose of ≥ 11.0 mmol/l. Blood sam-
ples were collected in the early morning. HbA1c and
glucose in plasma were determined using fully auto-
mated analysers (Hitachi 747 and 911; Hitachi, Ltd,
Tokyo, Japan). HbA1c results were reported in DCCT
units as percentage of haemoglobin, HbA1c can also be
expressed in mmol/mol, according to the IFCC reference
method. DCCT units can be converted into IFCC units
using the following equation: IFCC-HbA1c (mmol/
mol) = [DCCT-HbA1c (%) - 2.15] x 10.929.
Characteristics of participants and possible confounders
At baseline, all participants were visited by a research
nurse at their place of residence for interviews and per-
formance tests: information on income and education
was obtained; the measurements for body mass index
(BMI) were done for all participants. Education levels
were dichotomized into high and low. The category
“high” consisted of participants who had more years of
education than elementary school only. Elementary
school or less years of education were considered as
“low”. Scales of income were dichotomised into high and
low. Smoking history was dichotomized in never and
ever. The category “ever” consisted of participants who
were current or past smokers. For alcohol drinking
habits, units of alcohol per week were listed. For each
participant, the total number of comorbidities was calcu-
lated using medical histories obtained from the general
practitioner or treating nurses and included cardiovascu-
lar comorbidities, chronic obstructive pulmonary disease
(COPD), Parkinson, cancer, arthritis.
The sumscore of cardiovascular comorbidities con-
sisted of hypertension, myocardial infarction, angina
pectoris, claudicatio intermittens, arterial surgery and
stroke. In addition, information on the use of medication
was obtained from the participant’s pharmacist. Blood
samples were collected early in the morning under non-
fasting conditions. Plasma levels of C-reactive protein
(CRP) were measured with the use of a fully automated
Hitachi 911 device.
Statistical analysis
The associations between CMV infection (expressed as
CMV seropositivity and as CMV IgG antibody level) and
indicators of glucose regulation (diagnosis of type 2 dia-
betes, level of HbA1c and non-fasting glucose level)
were assessed using logistic regression analysis and lin-
ear regression analysis with adjustments in three models.
First, analysis was not adjusted for possible confounders
(crude model). Second, the analysis was adjusted for
gender and factors known to be associated with CMV
infection and glucose regulation (income, education,
smoking, BMI, total number of comorbidities (sumscore
of cardiovascular comorbidities, COPD, Parkinson,
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estimate of the severity of the comorbidities). Third,
CRP was included to further elucidate the effect of sys-
temic inflammation on the relationship between CMV
infection and glucose regulation. Distributions of con-
tinuous variables were examined for normality and loga-
rithmically transformed where appropriate (for CRP and
non-fasting glucose). The statistical Package for the So-
cial Sciences (SPSS) program for windows, version 17
was used for data analysis. Figures were drawn using
Graph Pad Prism version 5. P-values < 0.05 were consid-
ered statistically significant.
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